Back Back
Future LA HIV Care
The Future of Long-Acting HIV Care: What’s Still Needed

Released: December 22, 2022

Expiration: December 21, 2023

Yvonne Gilleece
Yvonne Gilleece, MB, BCh, BAO, FRCP
Cristina Mussini
Cristina Mussini, MD
Babafemi Taiwo
Babafemi Taiwo, MBBS
Darrell H S Tan
Darrell H S Tan, MD, FRCPC, PhD
Activity Information

Activity

Progress
1
Course Completed

In this episode, an international expert panel shares their thoughts on what will be needed from future long-acting HIV treatment and prevention strategies to address populations who are not eligible for currently available long-acting options. The faculty members also discuss important considerations for leveraging long-acting HIV approaches to address care inequities across different populations.

Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; essential considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection, such as the role of the lead-in phase, new guideline recommendations for monitoring during PrEP, and patient care and follow-up after PrEP discontinuation; and important considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium.